Neutrophil Extracellular Traps Are Induced in a Psoriasis Model of Interleukin-36 Receptor Antagonist-deficient Mice
Authors
Affiliations
Loss-of-function mutations in the interleukin (IL)-36 gene IL36RN are associated with psoriasis. The importance of neutrophil extracellular traps (NETs), web-like structures composed of neutrophil DNA, in the pathogenesis of psoriasis has been unclear. Here, we aimed to clarify the role of NET signaling in the deficiency of IL36 receptor antagonist (DITRA). We evaluated the severity of psoriasis-like lesions induced by imiquimod cream treatment in Il36rn mice. The mRNA levels of psoriasis-related cytokines were measured via real-time reverse transcription polymerase chain reaction, and the effects of Cl-amidine, a peptidyl arginine deiminase 4 (PAD4) inhibitor, on psoriasis-like lesions were evaluated. PAD4 is a histone-modifying enzyme that is involved in NET formation. Psoriasis area and severity index scores, epidermal thickness, and infiltrated neutrophil counts were significantly increased in Il36rn mice; NET formation was confirmed pathologically. Several cytokines and chemokines were upregulated in the skin lesions of Il36rn mice and Cl-amidine treatment improved these psoriasis-like lesions. These results suggest that NET formation plays an important role in the pathology of psoriasis-like lesions in these mice and might represent a promising therapeutic target for DITRA.
Histone Modifications and DNA Methylation in Psoriasis: A Cellular Perspective.
Pan J, Chen S, Chen X, Song Y, Cheng H Clin Rev Allergy Immunol. 2025; 68(1):6.
PMID: 39871086 DOI: 10.1007/s12016-024-09014-1.
IWR-1 attenuates the promotional effect of IL-36γ in a mouse model of psoriasis.
Wang W, Gao Y, Zheng X, Jin H BMC Immunol. 2024; 25(1):78.
PMID: 39578777 PMC: 11585084. DOI: 10.1186/s12865-024-00669-1.
Neutrophil extracellular traps and neutrophilic dermatosis: an update review.
Li S, Ying S, Wang Y, Lv Y, Qiao J, Fang H Cell Death Discov. 2024; 10(1):18.
PMID: 38195543 PMC: 10776565. DOI: 10.1038/s41420-023-01787-2.
Targeting IL-36 in Inflammatory Skin Diseases.
Fukaura R, Akiyama M BioDrugs. 2023; 37(3):279-293.
PMID: 36867370 DOI: 10.1007/s40259-023-00587-5.
Hasegawa Y, Iwata Y, Fukushima H, Tanaka Y, Watanabe S, Saito K Sci Rep. 2022; 12(1):13384.
PMID: 35927298 PMC: 9352770. DOI: 10.1038/s41598-022-16449-z.